Stake logo

TSVT

2SEVENTY BIO INC

About TSVT

2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development and commercialization of transformative treatments for cancer. The Company is advancing multiple clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia, and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as multiple preclinical programs, including bbT4015, an engineered chimeric antigen receptor (CAR) T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb (BMS), the Company is delivering ABECMA to multiple myeloma patients in the United States for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and a cyclic ADP ribose hydrolase (anti-CD38) monoclonal antibody.

Buy US stocks in Australia starting with TSVT. Open an account and start investing today!

Market Capitalisation

$535.76M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

681.87K

High today

$15.25

Low today

$14.16

Open price

$14.16

52-week high

$19.33

52-week low

$8.44


TSVT FAQs

One share of 2SEVENTY BIO INC is valued at $14.99.

The ticker symbol for 2SEVENTY BIO INC is TSVT.

To buy TSVT stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in TSVT

As of 07/02/2023 2SEVENTY BIO INC has a market cap of $536M.

The 2SEVENTY BIO INC 52-week high stock price is $19.33.

The 2SEVENTY BIO INC 52-week low stock price is $8.44.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.